Women's health and contraception represent some of the highest-yield clinical domains in both the RACGP Applied Knowledge Test (AKT) and Key Feature Problem (KFP) examinations. Because contraception counseling, antenatal care, and menopause management form a significant portion of daily general practice in Australia, examiners consistently design multiple questions around these topics.
Many candidates lose marks in this domain due to unfamiliarity with the Medical Eligibility Criteria (MEC) for contraceptive use, particularly regarding absolute contraindications for combined hormonal contraception. Candidates also frequently make mistakes in KFP answers by miscalculating antenatal screening timelines or mismanaging hormone replacement therapy (HRT).
This clinical revision guide provides a comprehensive breakdown of high-yield women's health topics, maps them to current Australian guidelines (Family Planning Alliance Australia, RANZCOG, RACGP Red Book), and details the examiner-reported errors you must avoid to secure a passing score.
Contraception Selection: MEC Eligibility Criteria
Choosing the appropriate contraceptive method is a core clinical skill tested in both exams. You must apply the Medical Eligibility Criteria (MEC) framework, which categorises patient risk into four levels:
- MEC 1: No restriction for the use of the contraceptive method.
- MEC 2: Advantages of using the method generally outweigh the theoretical or proven risks.
- MEC 3: Theoretical or proven risks generally outweigh the advantages. Use requires expert clinical judgment or specialist referral.
- MEC 4: An unacceptable health risk. The method must not be used.
High-Yield MEC 4 Absolute Contraindications for Combined Hormonal Contraception (COC/Patch/Ring)
You must memorize the classic MEC 4 conditions, as selecting combined hormonal methods for these patients represents a severe clinical safety error:
1. Cardiovascular Risk Factors
- Migraine with aura: At any age, due to a significantly increased risk of ischemic stroke.
- Age 35 years or older AND smoking 15 or more cigarettes per day.
- History of venous thromboembolism (VTE) or known thrombogenic mutations.
- Established ischemic heart disease, history of stroke, or peripheral vascular disease.
- Severe or uncontrolled hypertension (systolic 160 mmHg or greater, or diastolic 100 mmHg or greater).
2. Systemic and Hepatic Conditions
- Active breast cancer (within 5 years).
- Severe cirrhosis, hepatocellular adenoma, or malignant hepatoma.
- Diabetes mellitus with microvascular complications (retinopathy, nephropathy, neuropathy) or disease duration greater than 20 years.
LARC and Non-Hormonal Alternatives
- Copper Intrauterine Device (Cu-IUD): MEC 1 for almost all systemic conditions, including history of VTE, breast cancer, migraine with aura, and cardiovascular disease.
- Levonorgestrel Intrauterine System (Mirena): MEC 1 for most cardiovascular conditions, but classified as MEC 4 for active breast cancer.
- Etonogestrel Subdermal Implant (Implanon): Excellent long-acting option, MEC 1 for migraine with aura and VTE history.
Routine Antenatal Care: Screening Schedules
Antenatal care is a highly structured curriculum area. KFP questions frequently require you to outline the routine investigations and screening timelines for uncomplicated pregnancies based on RANZCOG and RACGP guidelines.
Standard Antenatal Screening Timeline
- First Visit / Booking Visit (preferably prior to 10 weeks): Full blood count (FBC), blood group and antibody screen, rubella immunity, syphilis serology (VDRL/RPR), hepatitis B and C serology, HIV screening, urine analysis and midstream urine culture (screening for asymptomatic bacteriuria), and ferritin.
- First Trimester Screening (11 to 13+6 weeks): Combined screening (Nuchal translucency ultrasound + maternal serum screening PAPP-A and free beta-hCG) or Non-Invasive Prenatal Testing (NIPT cfDNA from 10 weeks onwards).
- Second Trimester Morphology Scan (18 to 20 weeks): High-resolution ultrasound to screen for structural fetal anomalies and placental localization.
- Gestational Diabetes Screening (24 to 28 weeks): A 75g 2-hour fasting OGTT. Gestational diabetes is diagnosed if fasting glucose is 5.1 mmol/L or greater, 1-hour glucose is 10.0 mmol/L or greater, or 2-hour glucose is 8.5 mmol/L or greater.
- Anti-D Prophylaxis (Rh-negative unsensitised women): Routine doses administered at 28 weeks and 34 weeks, and within 72 hours of any sensitising event.
Menopause Management: MHT and Regimens
Menopausal Hormone Therapy (MHT) decisions are frequently tested. You must understand the indications, contraindications, and appropriate regimens based on whether the patient has an intact uterus.
1. Regimen Selection Rule
- Intact Uterus: You must prescribe combined MHT (estrogen + progestogen). Estrogen-only therapy in a patient with a uterus causes unopposed endometrial stimulation and carries a very high risk of endometrial hyperplasia and carcinoma.
- Post-Hysterectomy: Prescribe estrogen-only MHT.
2. Progestogen Regimen Types
- Sequential MHT (Cyclical): Prescribe for peri-menopausal women or those less than 1 year post-menopause. Estrogen is taken daily, and progestogen is added for 10 to 14 days of each month to induce a predictable withdrawal bleed.
- Continuous Combined MHT: Prescribe for post-menopausal women (greater than 1 year since last menstrual period) where both estrogen and progestogen are taken daily, resulting in amenorrhea.
3. Key MHT Contraindications
Do not prescribe MHT if the patient presents with active or previous history of breast cancer, active venous thromboembolism (VTE), unexplained vaginal bleeding, or active liver disease.
Cervical Screening: National Program Guidelines
The National Cervical Screening Program (NCSP) in Australia is a highly tested preventative health topic:
- Routine Screening: Primary human papillomavirus (HPV) DNA test every 5 years for asymptomatic women aged 25 to 74 years who have ever been sexually active.
- Self-Collection Option: All eligible screening participants have the option to choose self-collection of a vaginal swab.
- Management Pathway for HPV positive results:
- HPV 16 and/or 18 positive: Refer directly to colposcopy, regardless of liquid-based cytology (LBC) co-test results.
- HPV (not 16/18) positive: Perform an LBC co-test. If LBC is normal or low-grade, repeat the HPV test in 12 months. If LBC is high-grade, refer to colposcopy.
Top 5 Examiner-Reported Women's Health Errors
Official RACGP public exam reports highlight specific recurring mistakes that candidates make in women's health questions:
- 1Prescribing Combined Hormonal Contraception to Patients with Migraine with Aura
Candidates frequently fail to screen for aura symptoms (visual scotoma, sensory changes) when presented with a 28-year-old patient requesting the pill. Prescribing combined oral contraceptives to a patient with migraine with aura is a severe clinical error due to the highly elevated stroke risk. A progestogen-only pill or LARC must be selected.
- 2Prescribing Estrogen-Only Therapy to a Patient with an Intact Uterus
Candidates frequently prescribe estrogen-only patches or tablets for hot flushes in a patient who has a uterus, without adding a progestogen. This is a severe clinical error that exposes the patient to an unacceptable risk of endometrial cancer. Combined therapy is mandatory unless the patient has had a hysterectomy.
- 3Ordering Gestational Diabetes Screening at the Wrong Gestation
Candidates often select gestational diabetes screening (OGTT) at the initial booking visit (10 weeks) or at 36 weeks gestation for an average-risk uncomplicated pregnancy. Routine screening for gestational diabetes must be performed exactly at 24 to 28 weeks gestation. Early screening at the booking visit is only indicated for patients with high-risk factors.
- 4Failing to Administer Anti-D After Sensitising Events
In trauma or antepartum haemorrhage scenarios involving an Rh-negative pregnant patient, candidates frequently forget to order Anti-D or delay administration to wait for laboratory results. Anti-D must be administered within 72 hours of any sensitising event to prevent maternal alloimmunisation.
- 5Recommending Combined Pill for Smokers Aged 35 or Older
Candidates under exam pressure often prescribe the combined oral contraceptive pill to a 37-year-old patient who smokes 10 cigarettes a day. While smoking at age over 35 is MEC 3 for light smoking and MEC 4 for heavy smoking, the general recommendation is to avoid combined methods in this cohort due to elevated cardiovascular risk. A progestogen-only or barrier method is safer.
Frequently Asked Questions
What are the diagnostic thresholds for gestational diabetes in Australia?
Following a 75g oral glucose tolerance test (OGTT) at 24 to 28 weeks, gestational diabetes is diagnosed if fasting glucose is 5.1 mmol/L or greater, 1-hour glucose is 10.0 mmol/L or greater, or 2-hour glucose is 8.5 mmol/L or greater.
Why is migraine with aura an absolute contraindication for combined oral contraceptives?
Migraine with aura is associated with an intrinsic increase in stroke risk. Combined oral contraceptives, which contain estrogen, synergistically elevate this risk, making the use of combined hormonal methods an unacceptable health risk (MEC 4).
What MHT regimen should be prescribed for a woman with a uterus who is 6 months post-menopause?
For a peri-menopausal woman or one who is less than 12 months post-menopause with an intact uterus, a sequential (cyclical) combined MHT regimen is indicated to prevent irregular bleeding and protect the endometrium.
How often should routine cervical screening be performed in Australia?
Routine cervical screening using a primary HPV DNA test is recommended every 5 years for asymptomatic women aged 25 to 74 years who have ever been sexually active.
When should routine Anti-D prophylaxis be administered to an Rh-negative unsensitised pregnant woman?
Routine Anti-D prophylaxis is administered at 28 weeks and 34 weeks gestation, and within 72 hours of any potential sensitising event such as miscarriage, trauma, or antepartum haemorrhage.